Thrombolytic drugs in acute myocardial infarction

Clinical and Applied Thrombosis/Hemostasis

Volumn 6, Issue 1, 2000, Pages 1-13

  Iqbal, Omer ^a   Messmore, Harry ^a   Hoppensteadt, Debra ^a   Fareed, Jawed ^a   Wehrmacher, William ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; ANISTREPLASE; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; FIBRINOLYTIC AGENT; FIBROLASE; HEPARIN; LANOTEPLASE; PROUROKINASE; RECOMBINANT PLASMINOGEN ACTIVATOR; RETEPLASE; SARUPLASE; STAPHYLOKINASE; STREPTOKINASE; TENECTEPLASE; UNCLASSIFIED DRUG; UROKINASE; VAMPIRE BAT PLASMINOGEN ACTIVATOR;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; BLEEDING; DOSE RESPONSE; DRUG COST; DRUG HALF LIFE; DRUG MECHANISM; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; RAT; REVIEW; STROKE; THROMBOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY;

ANIMALS; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION;

EID: 0033975745     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/107602960000600101     Document Type: Review

References (130)

1. Sutton D, Young JWR. A concise textbook of clinical imaging, 2nd ed., St. Louis: Mosby, 1995.
2. Mruk JS, Zodhelyi P, Webster MCI. Does antithrombin therapy influence residual thrombus after thrombolysis of platelet rich thrombus? Effects of r-hirudin, heparin or aspirin. Circulation 1996;93:792.
3. Chesebro JH, Faster V. Dynamic thrombosis and thrombolysis, role of antithrombins. Circulation 1991;83:1815.
4. White HD, Aylward PE, Frey MJ, et al. On behalf of the hirulog early reperfusion/occlusion (HERO) trial investigators: randomized double-blind comparison of Hirulog vs heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Circulation 1997;96:2155.
5. Chesebro JH. Direct thrombin inhibition superior to heparin during and after thrombolysis, dose, duration and drug [Editorial]. Circulation 1997;96:2118.
6. Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures. Guidelines for the early management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart association. J Am Coll Cardiol 1990;16:249.
7. Cummins RO. Textbook of advanced cardiac life support. Dallas: American Heart association, 1994.
8. Fibrinolytic Therapy Trialists Collaborative Group.Indication for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet 1994;343:311.
9. National Heart Attack Alert Program Coordinating Committee. 60 minutes to treatment working group. Ann Emerg Med 1994; 23:311.
10. Paul L. Marino. The ICU book, 2nd ed. Baltimore: Williams & Wilkins, 1998.
11. Rogers WJ. Contemporary management of acute myocardial infarction. Am J Med 1995;99:195.
12. Gruppo Italiano per lo studio della stretochinasi nell Infarto Miocardico (GISSI): Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397.
13. ISIS-2, Second International Study of Infarct Survival Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988;2:349.
14. Wilcox RG, von der Lippe G, Olsson CG, et al. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Lancet 1988;2:525.
15. ISAM Study Group. A prospective trial of intravenous streptokinase in acute myocardial infarction (ISAM): mortality, morbidity and size at 21 days. N Engl J Med 1986;314:1465.
16. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet 1988;1:842.
17. Topol EJ. Which thrombolytic agent should we choose? Prog Cardiovasc Dis 1991;34:165.
18. Fears R, Ferres H, Glasgow E, et al. Monitoring of streptokinase resistance titre in acute myocardial infarction patients up to 30 months after giving streptokinase or anistreplase and related studies to measure specific antistreptokinase IgG. Br Heart J 1992; 68:167.
19. Hoffman JJ, Fears R, Bonnier JJ, et al. Significance of antibodies to streptokinase in coronary thrombolytic therapy with streptokinase or APSAC.Fibrinolysis 1988;2:203.
20. Fears R , Hearn J, Standring R, et al. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction. Am Heart J 1992;124:305.
21. Jalihal S, Morris GK. Antistreptokinase titres after intravenous streptokinase.Lancet 1990;335:184.
22. Topol EJ, Morris DC, Smalling RW, et al. A multicenter, randomized, placebo- controlled trial of a new form of intravenous recombinant tissue-type plasminogen activator (Activase) in acute myocardial Infarction. J Am Coll Cardiol 1987;91:205.
23. Anderson JL, Marshall HW, Askins JC, et al. A randomized trial of intravenous and intracoronary streptokinase in patients with acute myocardial infarction.Circulation 1984;70:606.
24. Anderson JL, Sorensen SG, Moreno FL, et al. Multicenter patency trial of intravenous anistreplase compared with streptokinase in acute myocardial infarction: the TEAM-2 Study Investigators. Circulation 1991;83:126.
25. Ribeiro E, Silva LA, Carneiro R, et al. Randomized trial of direct coronary angioplasty versus intravenous streptokinase in acute myocardial infarction. J Am Coll Cardiol 1993;22:376.
26. Tierney LM Jr, McPhee SJ, Papadakis MA, eds. Current medical diagnosis & treatment, 38th ed. Stamford, CT: Appleton & Lange, 1999.
27. Granger CB, Califf RM, Topol EJ. Thrombolytic therapy for acute myocardial infarction. A review. Drugs 1992;44:293.
28. Mathey DG, Schofer J, Sheehan FH, et al. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985;55:878.
29. Wall TC, Phillips HR, Stack RS, et al. Results of high dose intravenous urokinase for acute myocardial infarction. Am J Cardiol 1990;65:124.
30. Topol EJ, Califf RM, George BS, et al. Coronary arterial thrombolysis with combined infusion of recombinant tissue-type plasminogen activator and urokinase in patients with acute myocardial infarction (TAMI-2). Circulation 1988;77:1100.
31. Urokinase and Alteplase in Myocardial Infarction Collaborative Group (URALMI). Combination of urokinase and alteplase in the treatment of myocardial infarction. Coron Artery Dis 1991;2:225.
32. Califf RM, Topol EJ, Stack RS, et al. Evaluation of combination thrombolytic therapy and timing of cardiac catheterization in acute myocardial infarction: results of thrombolysis and angioplasty in myocardial infarction- Phase 5 randomized trial.Circulation 1991;83:1543.
33. Neuhaus KL, Tebbe U, Gottwik M, et al. Intravenous recombinant tissue plasminogen activator (t-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol 1988;12:581.
34. Whitlow PL, Bashore TM. Catheterization/Rescue Angioplasty Following Thrombolysis (CRAFT) Study: Acute myocardial infarction treated with recombinant tissue plasminogen activator versus urokinase [Abstract]. J Am Coll Cardiol 1991;17(Suppl): 276A.
35. Wall TC, Phillips HR, Stack RS, et al. Results of high dose intravenous urokinase for acute myocardial infarction. Am J Cardiol 1990;65:124.
36. Mathey DG, Schfer J, Sheehan FH, et al. Intravenous urokinase in acute myocardial infarction. Am J Cardiol 1985;55:878.
37. Topol EJ, Bell WR, Weisfeldt ML. Coronary thrombolysis with recombinant tissue- type plasminogen activator: a hematologic and pharmacologic study. Ann Intern Med 1985;103:837.
38. Topol EJ, Ciuffo AA, Pearson TA, et al. Thrombolysis with recombinant tissue-type plasminogen activator in atherosclerotic thrombotic occlusion. J Am Coll Cardiol 1985;5:85.
39. Neuhaus KL, Feuerer W, Jeep Tebbe S, et al. Improved thrombolysis with a modified dose regimen of recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1989;14:1566.
40. Bassand JP, Machercourt J, Cassagnes J, et al. Multicenter trial of intravenous anisoylated plasminogen streptokinase complex (APSAC) in acute myocardial infarction. Effects on infarct size and left ventricular function. J Am Coll Cardiol 1989;13:988.
41. Stringer KA. Biochemical and pharmacologic comparison of thrombolytic agents. Pharmacotherapy 1996;16(Pt 2):119S.
42. Koster RW, Collen AF, Hopkins GR, et al. Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost 1994;72:740.
43. Cutler D, Bode C, Runge MS. The promise of new genetically engineered plasminogen activators. J Vasc Interv Radiol 1995;6: 3S.
44. Sasahara AA, Barker WM, Weaver WD, et al. Clinical studies with the new glycosylated recombinant prourokinase. J Vasc Interv Radiol 1995;6(Suppl):84S.
45. Spieker M, Meyer J. Prourokinase fur die Infarkttherapie (prourokinase for treatment of acute myocardial infarction). Herz 1994;19:326.
46. Tebbe U, Michels R, Adgey J, et al. Randomized, double-blind study comparing saruplase with streptokinase therapy in acute myocardial infarction: the COMPASS equivalence trial. J Am Coll Cardiol 1998;31:487.
47. Vermeer F, Bar F, Windeler J, et al. Saruplase, a new fibrin specific thrombolytic agent: final results of the PASS study (1689 patients). Circulation 1993;88:I-292.
48. Bar FW, Meyer J, Vermeer F, et al. for the SESAM Study Group. Comparison of saruplase and alteplase in acute myocardial infarction. Am J Cardiol 1997;79:732.
49. PRIMI Trial Study Group. Randomized double blind trial of recombinant prourokinase against streptokinase in acute myocardial infarction. Lancet 1989;1:863.
50. Bode C, Peter K, Nordt T, et al. New developments in thrombolytic therapy.Fibrin Proteol 1997;1(Suppl 1):109.
51. Bode C, Runge MS, Schnermark S, et al. Conjugation to an antifibrin Fab' enhances fibrinolytic potency of single chain urokinase plasminogen activator. Circulation 1990;81:1974.
52. Ross AM. New plasminogen activators. A clinical review. Clin Cardiol 1999;22:165.
53. Ross AM, Coyne K, Moreya E, et al. for the GUSTO-1 Anglographic Investigators. Extended mortality benefit of early post-infarction reperfusion. Circulation 1998;97:1549.
54. Collen D. Thrombolytic therapy. Thromb Haemost 1997;78:742.
55. Lefkovits J, Topol EJ. Future directions in thrombolysis for myocardial infarction: what are the unanswered questions? Coron Artery Dis 1994;5:306.
56. Huber, Maure G. Thrombolytic therapy in acute myocardial infarction. Semin Thromb Hemost 1996;22:15.
57. Van de Werf F. TNK-t-PA: results of the phase II trials. TIMI 10B and ASSENT-I. Presented at the New Developments in Thrombolytic and Antithrombotic Therapy Satellite Symposium at the XIX Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.
58. Smalling RW. Molecular biology of plasminogen activators: what are the clinical implications of drug design? Am J Cardiol 1996;78(Suppl 12A):2.
59. The GUSTO-III Investigators. Comparison of reteplase for acute myocardial infarction. N Engl J Med 1997;337:118.
60. Bode C, Smalling RW, Berg G, et al., for the RAPID II Investigators. Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891.
61. White HD. Thrombolytic therapy and equivalence trials. J Am Coll Cardiol 1998;31:494.
62. Gurbel PA, Serbruany VL, Shustov AR, et al., for the GUSTO III Investigators. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction Treatment. J Am Coll Cardiol 1998; 31:1466.
63. Brenner SJ, Topol EJ. Third generation thrombolytic agents for acute myocardial infarction. In: Topol EJ, ed. Acute coronary syndromes. New York: Marcel Dekker, 1998:167.
64. Ogata N, Ogata Y, Hokamaki J, et al. Serial changes of plasminogen activator inhibitor activity in thrombolytic therapy for acute myocardial infarction: comparison between thrombolytic therapies with mutant tPA (Lanoteplase, BMS-200980) and recombinant tPA (alteplase). Circulation 1996;94(Suppl 1):1.
65. Thadani V. Lanoteplase: the In Time study. Presented at Myocardial Reperfusion X: Concepts and Controversies: Satellite symposium at the 46th Annual Scientific Session of the American College of Cardiology; March 14, 1997: Anaheim, California.
66. Neuhaus KL, van de Werf F. New thrombolytics ease treatment of MI. Modern Medicine 1999;67:49.
67. McCluskey ER, Keyt BA, Refino CJ, et al. Biochemistry, pharmacology, and initial clinical experience with TNK-tPA. In: Sasahara AA, Loscalzo J, eds. New Therapeutic Agents in Thrombosis and Thrombolysis. New York: Marcel Dekker Inc., 1997:475.
68. De Marco E, Rebuzi AG, Quaranta G, et al. Lack of procoagulant effect after TNK plasminogen activator in patients with acute myocardial infarction. Eur Heart J 1998;19(Suppl):5.
69. Ghali M, Sequeira RF, McKendall GR, et al., and the TIMI 10A Investigators. TNK- tissue plasminogen activator in acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction. TIMI 10A dose ranging trial. Circulation 1997;95:351.
70. Cannon C, McCabe CH, Gibson CM, et al. TNK-t-PA compared with front-loaded tissue plasminogen activator in acute myocardial infarction: primary results of the TIMI 10B trial. Circulation 1997;96(Suppl I):I.
71. Keyt BA, Paoni NF, Refino CJ, et al. A faster-acting and more potent form of tissue plasminogen activator. Proc Natl Acad Sci USA 1994;91:3670.
72. Topol EJ. Toward a new frontier in myocardial reperfusion therapy. Emerging platelet preeminence. Circulation 1998;97: 211.
73. De Marco E, Rebuzzi AG, Quaranta G, et al. Lack of procoagulant effect after TNK-plasminogen activator in patients with acute myocardial infarction. Ear Heart J 1998;19(Suppl):5.
74. Cannon CP, Mc Cabe CH, Gibson CM, et al., and the TIMI 10A investigators. TNK-tPA in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose ranging trial. Circulation 1997;95:351.
75. The GUSTO Angiographic investigators: The effects of tissue plasminogen activator, streptokinase or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615.
76. Smalling RW, Bode C, Kalbfleisch J, et al., and the RAPID investigators.More rapid, complete and stable coronary thrombolysis with bolus administration of reteplase compared with alteplase infusion in acute myocardial infarction. Circulation 1995; 91:2725.
77. Bode C, Smalling RW, Berg G, et al., for the RAPID II investigators.Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. Circulation 1996;94:891.
78. Cannon CP, Mc Cabe CH, Gibson CM, et al. TNK-tPA compared with front-loaded tissue plasminogen activator in acute myocardial infarction: primary results of the TIMI 10B trial. Circulation 1997;96(Suppl):1.
79. Gibson CM. A randomized prospective comparison of tPA with TNK-tPA using the TIMI Frame Count: results of TIMI-10B. Presented at the 70th Scientific sessions of the American Heart Association; November 9-12, 1997; Orlando, Florida.
80. Gibson CM, Cannon CP, Mc Cabe C, et al. A randomized prospective comparison of tPA with TNK using the TIMI frame count: Results of the TIMI 10B. Circulation 1997;96(Suppl I):1330.
81. Van de Werf F. TNK-tPA: results of the phase II trials. TIMI 10B and ASSENT-1. Presented at the New Development in Thrombolytic and Antithrombotic Therapy Satellite symposium at the XIX Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.
82. Collen D, Vanderschueren S, van de Werf F. Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Haemostasis 1996;26(Suppl 4):294.
83. Bode C, Peter K, Nordt T, et al. New developments in thrombolytic therapy. Fibrin Proteol 1997;11(Suppl 1):109.
84. Anderschueren S. Barrios L, Kerssinchai P, et al., for the STAR Trial Group. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction. Circulation 1995;92:2044.
85. Sako T, Tsuchida N. Nucleotide sequence of the streplokinase gene from staphylococcus aureus. Nucleic Acids Res 1983;11: 7679.
86. Behnke D, Gerlach D. Cloning and expression in Escherichia coli, Bacilus subtilis and streptococcus sanguis of a gene for staphylokinase: a bacterial plasminogen activator. Mol Gen Genet 1987;210:528.
87. Collen D, Zhao ZA, Holvoet P, et al. Primary structure and gene structure of staphylokinase. Fibrinolysis 1992;6:226.
88. Schlott B, Hartman M, Guhrs KM, et al. The thermostability of natural variants of bacterial plasminogen-activator staphylokinase. Eur J Biochem 1994;223:303.
89. Collen D, Van de Werf F. Coronary thrombolysis with recombinant staphylokinase in patients with evolving myocardial infarction. Circulation 1993;87:1850.
90. Vanderschueren S, Collen D, Van de Werf F. Coronary reperfusion in patients with an acute myocardial infarction following intravenous administration of recombinant staphylokinase [Abstract]. J Am Coll Cardiol 1994;23:315A.
91. Collen DC, Gold HK. New developments in thrombolytic therapy. Thromb Res 1990;(Suppl X):105.
92. Gulba DC, Bode C, Runge MS, et al. Thrombolytic agents - an overview. Ann Hematol 1996;73(Suppl I):59.
93. Lerakis S, Stoufer GA, Runge MS. New thrombolytics: what is under development? Biodrugs 1997;8:24.
94. Collen D. Staphylokinase: a potent, uniquely fibrin-selective thrombolytic agent. Nat Med 1998;4:279.
95. Gardel SJ, Ramjit DR, Stabilino II, et al. Effective thrombolysis without marked plasminemia after bolus intravenous administration of vampire bat salivary plasminogen activator in rabbits. Circulation 1991;84:244.
96. Mellott MJ, Stabilino II, Holahan M, et al. Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. Arterioscler Thromb 1992;12:212.
97. Kingston IB, Castro MJM, Anderson S. In vitro stimulation of tissue-type plasminogen activator by Alzhcimcr amyloid β-peptide analogues. Nat Med 1995;1:138.
98. Brodic BR, Stone GW, Morice MC, et al. Importance of time to reperfusion on outcomes after primary PTCA for acute myocardial infarction: results from stent PAMI [Abstract]. J Am Coll Cardiol 1999;33(Suppl A):353A.
99. Zeyer LI, Schroder R, Molhoek P, et al., for the HIT-4 Investigators. Noninvasive assessment of infarct-related artery patency after thrombolysis for acute myocardial infarction by ST resolution: results of the HIT-4 angiographic substudy [Abstract]. J Am Coll Cardiol 1999;33(Suppl A):324A.
100. Hudson MP, Granger CB, Pieper KS, et al. Reinfarction after thrombolytic therapy: experience from the GUSTO-1 and III Trials [Abstract]. J Am Coll Cardiol 1999;33(Suppl A):130.
101. Kostis JB, Liao WC, Beierle FA, et al. Single bolus regimen of lanoteplase (nPA) in acute myocardial infarction: hemostatic evaluation vs. he In Time Study [Abstract]. J Am Coll Cardiol 1999;2(Suppl A):131.
102. Owen J, Friedman KD, Grossman BA, et al. Thrombolytic therapy with tissue plasminogen activator or streptokinase induces transient thrombin activity. Blood 1988;72:616.
103. Bleich SD, Nichols TC, Schumacher RR, et al. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412.
104. Hsia J, Hamilton WP, Kleiman N. et al., for the Heparin-Aspirin Reperfusion Trial (HART) investigators: a comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433.
105. De Bono DP, Simoons ML, Tijssen J, et al., for the European Cooperative study Group (ECSG). Effect of early intravenous heparin on coronary patency, infarct size and bleeding complications after alteplase thrombolysis: results of a randomized boubleblind European Cooperative Study Group Trial. Br Heart J 1992;67:1212.
106. Special report on reperfusion in acute myocardial infarction of the International Society and Federation of Cardiology and World Health Organization Task Force on Myocardial reperfusion. Circulation 1994;90:2091.
107. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988:2:349.
108. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function and survival after acute myocardial infarction. N Engl J Med 1993;329:1615.
109. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995;49:856.
110. Weitz JI, Califf RM, Ginsberg JS, et al. New antithrombotics. Chest 1995;108:471S.
111. Lijnen HR, Collen D. Experimental studies in thrombolysis and fibrinolysis. Curr Opin Cardiol 1993:8:613.
112. Coller BS. The role of platelets in arterial thrombosis and the rationale for blockade of platelet GPIIb/IIIa receptors as antithrombotic therapy. Eur Heart J 1995;16(Suppl L):11.
113. Jang IK, Fuster V, Gold HK. Antiplatelet agents. Coron Artery Dis 1992;3:1030.
114. Kleiman NS, Ohman EM, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy: results of the TAMI 8 Pilot study. J Am Coll Cardiol 1993:22:381.
115. The GUSTO Investigators. An International randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673.
116. Neuhaus KL, von Essen R, Tebbe U, et al. Safety observations from the pilot phase of the randomized r-hirudin for improvement of thrombolysis (HIT-III) study: a study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausartze (ALKK). Circulation 1994;90:1638.
117. Global Use of Strategies to Open Coronary Arteries (GUSTO) IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994;90:1631.
118. Antman EM, for the TIMI 9A Investigators. Hirudin in acute myocardial infarction: safety report from thrombolysis and thrombin inhibition in myocardial infarction (TIMI) 9A trial. Circulation 1994;90:1624.
119. Ohman EM, Califf Rm, Topol EJ, et al. Consequences of reocclusion after successful reperfusion therapy in acute myocardial infarction. Circulation 1990;82:781.
120. Bode C, Hudelmayer M, Mehwald P, et al. Fibrin-targeted recombinant hirudin inhibits fibrin deposition on experimental clots more efficiently than recombinant hirudin. Circulation 1994;90: 1956.
121. Loayza SL, Trikha M, Markland FS, et al. Resolution of isoforms of natural and recombinant fibrolase, the fibrinolytic enzyme from Agkistrodon contortrix snake venom, and comparison of their EDTA sensitivities. J Chromatgr Biomed Appl 1994;662: 227.
122. Markland FS, Friedrichs GS, Pewitt SR, et al. Thrombolytic effects of recombinant fibrolase or APSAC in a canine model of carotid artery thrombosis. Circulation 1994;90:2448.
123. Chesebro JH, Badimon JJ. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease. N Engl J Med 1998;338: 1539.
124. Iqbal O. New anticoagulants for adjunct use in angiography. In: Pifarre R, ed. New anticoagulants for the cardiovascular patient. Philadelphia: Hanley & Belfus, Inc., 1997:471.
125. Iqbal O. Thrombolytic drugs offer new therapeutic options. Diagnostic Imaging 1998;79:59.
126. Wehrmacher WH. Anticoagulants in myocardial infarction. Am J Cardiol 1958;2:646.
127. Wehrmacher WH. Myocardial infarction patterns, ch 14 (13 slides). In: Clinical electrocardiography [slide]. Edited by James WE, Wolf PS, Tucker CE. Parker, CO: Post-graduate Institute for Medicine, 1981.
128. Messmore HL, Wehrmacher WH. Therapeutic use of low molecular weight heparins. Semin Thromb Hemost 1993;19(Suppl 1):97.
129. Wehrmacher WH, Moncada R, Fareed J, et al. Studies on the intravascular contrast media induced release of tissue plasminogen activator: Implications on the hemostatic processes. Federation Proceedings 1985;44:4.
130. Schnee JM, Runge MS, Matsueda GR, et al. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci USA 1987;84:6904.